Rockefeller Capital Management
ACAD icon

Rockefeller Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rockefeller Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Sell
1,015,420
-11,937
-1% -$263K 0.04% 406
2026
Q1 		$22.9M Sell
1,027,357
-85,683
-8% -$2.05M 0.04% 407
2025
Q4 		$29.7M Buy
1,113,040
+76,727
+7% +$1.83M 0.05% 335
2025
Q3 		$22.1M Sell
1,036,313
-128,081
-11% -$3.03M 0.04% 384
2025
Q2 		$25.1M Buy
1,164,394
+26,300
+2% +$489K 0.06% 319
2025
Q1 		$18.9M Sell
1,138,094
-25,361
-2% -$461K 0.05% 380
2024
Q4 		$21.3M Buy
1,163,455
+23,521
+2% +$380K 0.06% 331
2024
Q3 		$17.5M Buy
1,139,934
+185,684
+19% +$3.1M 0.05% 383
2024
Q2 		$15.5M Buy
954,250
+165,798
+21% +$2.68M 0.04% 391
2024
Q1 		$14.6M Buy
788,452
+232,115
+42% +$5.75M 0.04% 407
2023
Q4 		$17.4M Buy
556,337
+51,164
+10% +$1.22M 0.06% 316
2023
Q3 		$10.5M Buy
505,173
+100,884
+25% +$2.74M 0.04% 404
2023
Q2 		$9.68M Sell
404,289
-76,591
-16% -$1.7M 0.04% 437
2023
Q1 		$9.05M Buy
480,880
+17,239
+4% +$328K 0.04% 439
2022
Q4 		$7.38M Buy
463,641
+4,811
+1% +$75.2K 0.04% 441
2022
Q3 		$7.51M Buy
458,830
+23,595
+5% +$382K 0.04% 438
2022
Q2 		$6.13M Buy
435,235
+117,500
+37% +$2.19M 0.03% 459
2022
Q1 		$7.69M Buy
317,735
+15,239
+5% +$369K 0.04% 436
2021
Q4 		$7.06M Buy
302,496
+21,268
+8% +$428K 0.03% 441
2021
Q3 		$4.67M Buy
281,228
+49,644
+21% +$957K 0.02% 498
2021
Q2 		$5.65M Buy
231,584
+226,222
+4,219% +$5.11M 0.03% 422
2021
Q1 		$138K Buy
5,362
+2,494
+87% +$110K ﹤0.01% 1467
2020
Q4 		$152K Sell
2,868
-3,094
-52% -$154K ﹤0.01% 1279
2020
Q3 		$245K Buy
5,962
+5,945
+34,971% +$257K ﹤0.01% 972
2020
Q2 		$1K Buy
+17
New +$816 ﹤0.01% 2407
2019
Q2 		– Sell
-68
Closed -$2K – 1630
2019
Q1 		$2K Buy
+68
New +$1.59K ﹤0.01% 1762

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rockefeller Capital Management's ACAD Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Acadia Pharmaceuticals (ACAD) stake by 1.2% in Q2 2026, selling an estimated $263K and leaving 1,015,420 shares worth $25.7M. The position accounts for 0.04% of the portfolio, ranked #406.

Rockefeller Capital Management first reported a position in ACAD in Q1 2019 and has held it in 26 quarters since. The position peaked at $29.7M in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Rockefeller Capital Management held 1,015,420 shares of Acadia Pharmaceuticals worth $25.7M as of Q2 2026.
  • Rockefeller Capital Management sold 11,937 Acadia Pharmaceuticals shares in Q2 2026, an estimated $263K.
  • Acadia Pharmaceuticals made up 0.04% of Rockefeller Capital Management's portfolio in Q2 2026, its #406 holding.
  • Rockefeller Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Rockefeller Capital Management's Acadia Pharmaceuticals position peaked at $29.7M in Q4 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.